| 肖成贤,董 滨,张爱迪,张俊湖,孙 瑛.血清α-syn、Aβ1-42、SSA在帕金森病患者中的表达及与认知功能损害的关系[J].现代生物医学进展英文版,2021,(14):2787-2791. |
| 血清α-syn、Aβ1-42、SSA在帕金森病患者中的表达及与认知功能损害的关系 |
| The Expression of Serum A-Syn, AB1-42 and SSA in Patients with Parkinson's Disease and Their Relationship with Cognitive Impairment |
| Received:February 03, 2021 Revised:February 28, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.14.040 |
| 中文关键词: 帕金森病 认知功能损害 α-突触核蛋白 β淀粉样蛋白1-42 淀粉样蛋白A |
| 英文关键词: Parkinson's disease Cognitive impairment α -synuclein Beta amyloid protein 1-42 Serum amyloid A |
| 基金项目:山东省医药卫生科技发展计划项目（2017WS140） |
|
| Hits: 872 |
| Download times: 456 |
| 中文摘要: |
| 摘要 目的：探讨血清α-突触核蛋白（α-synuclein，α-syn）、β淀粉样蛋白1-42（β-amyloid 1-42，Aβ1-42）、淀粉样蛋白A（serum amyloid A，SSA）在帕金森病患者中的表达及与认知功能损害的关系。方法：收集本院2018年7月~2020年11月收治的136例帕金森病患者为病例组，依据Hoehn-Yahr（H-Y）分级分为早期组（n=76）与中晚期组（n=60）；依据蒙特利尔认知评估量表（Montreal Cognitive Assessment Scale，MoCA）分为认知功能正常组（n=94）与认知功能损害组（n=42）。另选同期本院体检正常者105例纳入对照组。对比各组血清α-syn、SSA、Aβ1-42水平及MoCA，并用Pearson相关系数分析病例组患者血清α-syn、SSA、Aβ1-42水平与MoCA的相关性，用受试者工作特征曲线（receiver operating characteristic curve，ROC）分析血清α-syn、SSA、Aβ1-42水平对帕金森病和认知功能损害的诊断价值。结果：病例组血清α-syn、SSA水平高于对照组，差异有统计学意义（P<0.05）；病例组Aβ1-42、MoCA评分低于对照组（P<0.05）。病例组晚期患者血清α-syn、SSA水平高于早期患者（P<0.05）；病例组晚期患者Aβ1-42、MoCA评分低于早期患者，差异有统计学意义（P<0.05）。病例组有认知功能损害患者血清α-syn、SSA水平高于认知功能正常患者（P<0.05）；病例组有认知功能损害患者Aβ1-42、MoCA评分低于认知功能正常患者（P<0.05）。病例组患者血清α-syn、SSA与MoCA均呈正相关（P<0.05），Aβ1-42与MoCA呈正相关（P<0.05）。血清α-syn、SSA、Aβ1-42水平对帕金森病诊断的曲线下面积分别为0.858、0.821、0.785；血清α-syn、SSA、Aβ1-42水平对帕金森病认知功能损害预测的曲线下面积分别为0.877、0.825、0.783。结论：帕金森病患者血清α-syn、SSA、Aβ1-42水平较健康者变化明显，且可能和帕金森病的诊断、病情进展和认知功能损害有一定关系。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression of serum α-synuclein (α-syn), β-amyloid 1-42(Aβ1-42) and serum amyloid A (SSA) in patients with Parkinson's disease and their relationship with cognitive impairment. Methods: 136 patients with Parkinson's disease admitted in our hospital from July 2018 to November 2020 were collected as case group, and divided into early stage group (n=76) and middle and late stage group (n = 60) according to Hoehn-Yahr(H-Y) grading. According to Montreal Cognitive Assessment Scale (MoCA), the patients were divided into normal cognitive function group (n=94) and cognitive impairment group (n=42). Another 105 cases with normal physical examination in the same period were included in the control group. The levels of serum α-syn, SSA, Aβ1-42 and MoCA in each group were compared. Pearson correlation coefficient was used to analyze the correlation between the levels of serum α-syn, SSA, Aβ1-42 and MoCA. The receiver operating characteristic curve (ROC) was used to analyze the diagnostic value of serum α-syn, SSA, Aβ1-42 in Parkinson's disease and cognitive impairment. Results: The levels of serum α-syn and SSA in case group were higher than those in control group, the difference was statistically significant (P<0.05). The Aβ1-42 and MoCA scores in the case group were lower than those in the control group (P<0.05). Serum α-syn and SSA levels in patients with advanced stage were higher than those in patients with early stage (P<0.05). The scores of Aβ1-42 and MoCA in late patients were lower than those in early patients, the difference was statistically significant (P<0.05). Serum α-syn and SSA levels in patients with cognitive impairment were higher than those in patients with normal cognitive function (P<0.05). The scores of Aβ1-42 and MoCA in patients with cognitive impairment were lower than those in patients with normal cognitive function (P<0.05). Serum α-syn, SSA were positively correlated with MoCA (P<0.05), and Aβ1-42 was positively correlated with MoCA (P<0.05). The areas under the curve of serum α-syn, SSA and Aβ1-42 levels for diagnosis of Parkinson's disease were 0.858, 0.821 and 0.785. The areas under the curve for predicting cognitive impairment of Parkinson's disease by serum α-syn, SSA and Aβ1-42 levels were 0.877, 0.825 and 0.783. Conclusion: Serum levels of α-syn, SSA and Aβ1-42 in patients with Parkinson's disease are significantly different from those in healthy people, which may be related to the diagnosis, progression and cognitive impairment of Parkinson's disease. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
